Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.

Jin M, Yu Y, Qi H, Xie Y, Su N, Wang X, Tan Q, Luo F, Zhu Y, Wang Q, Du X, Xian CJ, Liu P, Huang H, Shen Y, Deng CX, Chen D, Chen L.

Hum Mol Genet. 2012 Dec 15;21(26):5443-55. doi: 10.1093/hmg/dds390. Epub 2012 Sep 26.

2.

HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.

Ota S, Zhou ZQ, Romero MP, Yang G, Hurlin PJ.

Hum Mol Genet. 2016 Oct 1;25(19):4227-4243. doi: 10.1093/hmg/ddw255. Epub 2016 Aug 9.

PMID:
27506979
3.

Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.

Meyer AN, McAndrew CW, Donoghue DJ.

Cancer Res. 2008 Sep 15;68(18):7362-70. doi: 10.1158/0008-5472.CAN-08-0575.

4.

Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.

Xie Y, Su N, Jin M, Qi H, Yang J, Li C, Du X, Luo F, Chen B, Shen Y, Huang H, Xian CJ, Deng C, Chen L.

Hum Mol Genet. 2012 Sep 15;21(18):3941-55. doi: 10.1093/hmg/dds181. Epub 2012 May 24.

PMID:
22634226
6.

Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia.

Guo C, Degnin CR, Laederich MB, Lunstrum GP, Holden P, Bihlmaier J, Krakow D, Cho YJ, Horton WA.

Cell Signal. 2008 Aug;20(8):1471-7. doi: 10.1016/j.cellsig.2008.04.001. Epub 2008 Apr 10.

7.

Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice.

Iwata T, Li CL, Deng CX, Francomano CA.

Hum Mol Genet. 2001 Jun 1;10(12):1255-64.

PMID:
11406607
9.

Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.

Matsushita M, Kitoh H, Ohkawara B, Mishima K, Kaneko H, Ito M, Masuda A, Ishiguro N, Ohno K.

PLoS One. 2013 Dec 4;8(12):e81569. doi: 10.1371/journal.pone.0081569. eCollection 2013.

10.

Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II.

Shung CY, Ota S, Zhou ZQ, Keene DR, Hurlin PJ.

Hum Mol Genet. 2012 Nov 1;21(21):4628-44. doi: 10.1093/hmg/dds305. Epub 2012 Jul 26.

PMID:
22843502
11.

Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.

Su WC, Kitagawa M, Xue N, Xie B, Garofalo S, Cho J, Deng C, Horton WA, Fu XY.

Nature. 1997 Mar 20;386(6622):288-92.

PMID:
9069288
12.

A case of thanatophoric dysplasia type 2: a novel mutation.

Gülaşı S, Atıcı A, Çelik Y.

J Clin Res Pediatr Endocrinol. 2015 Mar;7(1):73-6. doi: 10.4274/jcrpe.1703.

13.
14.

Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.

Harada D, Yamanaka Y, Ueda K, Nishimura R, Morishima T, Seino Y, Tanaka H.

Bone. 2007 Aug;41(2):273-81. Epub 2007 Feb 9.

PMID:
17561467
15.

FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.

Matsushita T, Wilcox WR, Chan YY, Kawanami A, Bükülmez H, Balmes G, Krejci P, Mekikian PB, Otani K, Yamaura I, Warman ML, Givol D, Murakami S.

Hum Mol Genet. 2009 Jan 15;18(2):227-40. doi: 10.1093/hmg/ddn339. Epub 2008 Oct 15.

16.

FGFR3 induces degradation of BMP type I receptor to regulate skeletal development.

Qi H, Jin M, Duan Y, Du X, Zhang Y, Ren F, Wang Y, Tian Q, Wang X, Wang Q, Zhu Y, Xie Y, Liu C, Cao X, Mishina Y, Chen D, Deng CX, Chang Z, Chen L.

Biochim Biophys Acta. 2014 Jul;1843(7):1237-47. doi: 10.1016/j.bbamcr.2014.03.011. Epub 2014 Mar 20.

17.

Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.

Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ.

Nat Genet. 1995 Mar;9(3):321-8.

PMID:
7773297
18.

Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.

Khnykin D, Olsnes S.

Growth Factors. 2006 Jun;24(2):111-9.

PMID:
16801131
19.

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.

Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Moore S, Huntly BJ, Fabbro D, Anderson KC, Griffin JD, Gilliland DG.

Oncogene. 2005 Dec 15;24(56):8259-67.

PMID:
16091734
20.

Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Foldynova-Trantirkova S, Wilcox WR, Krejci P.

Hum Mutat. 2012 Jan;33(1):29-41. doi: 10.1002/humu.21636. Epub 2011 Nov 16. Review.

Supplemental Content

Support Center